Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes

International Journal of COPD

Volumn 10, Issue , 2015, Pages 917-923

  Zhang, Jian Qing ^a   Zhang, Jia Qiang ^a   Liu, Hua ^a   Zhao, Zhi Huan ^a   Fang, Li Zhou ^a   Liu, Ling ^a   Fu, Wei Ping ^a   Shu, Jing Kui ^a   Feng, Jia Gang ^a   Dai, Lu Ming ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; Microsomal epoxide hydrolase; N acetylcysteine; Polymorphism

Indexed keywords

ACETYLCYSTEINE; EPOXIDE HYDROLASE; ANTIOXIDANT; EPHX1 PROTEIN, HUMAN;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; QUALITY OF LIFE; SCORING SYSTEM; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOMATOLOGY; TREATMENT RESPONSE; CONVALESCENCE; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; LUNG; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ACETYLCYSTEINE; AGED; ANTIOXIDANTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPOXIDE HYDROLASES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929412545     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S79710     Document Type: Article

References (33)

1. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):50–60.
2. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–e64.
3. Vestbo J, Hurd SS, Agusti AG, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365.
4. Zhong L, Zhang YP, Fu WP, Dai LM, Sun C, Wang YQ. The relationship between GSTP1 I105V polymorphism and COPD: a reappraisal. Am J Respir Crit Care Med. 2010;181(7):763–765.
5. Zhong L, Fu WP, Sun C, Dai LM, Zhang YP. Absence of association between SERPINE2 genetic polymorphisms and chronic obstructive pulmonary disease in Han Chinese: a case-control cohort study. BMC Med Genet. 2009;10:66.
6. Fu WP, Sun C, Dai LM, Yang LF, Zhang YP. Relationship between COPD and polymorphisms of HOX-1 and mEPH in a Chinese population. Oncol Rep. 2007;17(2):483–488.
7. Li H, Fu WP, Hong ZH. Microsomal epoxide hydrolase gene polymorphisms and risk of chronic obstructive pulmonary disease: a comprehensive meta-analysis. Oncol Lett. 2013;5(3):1022–1030.
8. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004;23(4):629–636.
9. Ueno T, Yamada M, Igarashi Y, Ogawa T. N-acetyl cysteine protects osteoblastic function from oxidative stress. J Biomed Mater Res A. 2011;99(4):523–531.
10. van Overveld FJ, Demkow U, Gorecka D, de Backer WA, Zielinski J. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J Physiol Pharmacol. 2005;56 Suppl 4:135–142.
11. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5):795–798.
12. Pela R, Calcagni AM, Subiaco S, Isidori P, Tubaldi A, Sanguinetti CM. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999;66(6):495–500.
13. Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144(1):106–118.
14. Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2(3):187–194.
15. Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest. 2009;136(2):381–386.
16. Schermer T, Chavannes N, Dekhuijzen R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009;103(4):542–551.
17. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552–1560.
18. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet. 1997;350(9078):630–633.
19. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med. 1995;152(3):1107–1136.
20. Park JY, Chen L, Wadhwa N, Tockman MS. Polymorphisms for microsomal epoxide hydrolase and genetic susceptibility to COPD. Int J Mol Med. 2005;15(3):443–448.
21. Rodriguez F, Jardi R, Costa X, et al. Detection of polymorphisms at exons 3 (Tyr113 –.His) and 4 (His139 –.Arg) of the microsomal epoxide hydrolase gene using fluorescence PCR method combined with melting curves analysis. Anal Biochem. 2002;308(1):120–126.
22. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Pare PD. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med. 2001;163(2):469–473.
23. Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A, Yamakido M. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med. 2000;5(1):49–53.
24. Maekawa K, Itoda M, Hanioka N, et al. Non-synonymous single nucleotide alterations in the microsomal epoxide hydrolase gene and their functional effects. Xenobiotica. 2003;33(3):277–287.
25. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet. 1994;3(3):421–428.
26. De Backer J, Vos W, Van Holsbeke C, et al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. Int J Chron Obstruct Pulmon Dis. 2013;8:569–579.
27. Shen Y, Cai W, Lei S, Zhang Z. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis. COPD. 2014;11(3):351–358.
28. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16(2):253–262.
29. Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006;3(4):195–202.
30. Zuin R, Palamidese A, Negrin R, Catozzo L, Scarda A, Balbinot M. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Invest. 2005;25(6):401–408.
31. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res. 2001;2(1):20–26.
32. Sampsonas F, Karkoulias K, Kaparianos A, Spiropoulos K. Genetics of chronic obstructive pulmonary disease, beyond a1-antitrypsin deficiency. Curr Med Chem. 2006;13(24):2857–2873.
33. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008;371(9629):2013–2018.